Syndax Pharmaceuticals SNDX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's shares (diluted)?
- Syndax Pharmaceuticals (SNDX) reported shares (diluted) of 88.3M in Q1 2026.
- How has Syndax Pharmaceuticals's shares (diluted) changed year-over-year?
- Syndax Pharmaceuticals's shares (diluted) increased by 2.4% year-over-year, from 86.2M to 88.3M.
- What is the long-term trend for Syndax Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's shares (diluted) has grown at a 13.5% compound annual growth rate (CAGR), from 208.7M to 345.8M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.